Evaluation of Tropaeolin 000-1 as a Colorimetric Reagent for Assay of Duloxetine and Escitalopram in Solid Dosage Form
Abstract
Purpose: To explore the application of tropaeolin 000-1 reagent for the rapid, precise and accurate determination of duloxetine hydrochloride (DX) and escitalopram maleate (ECT).
Methods: Determination of DX and ECT was based on the formation of complexes between the dye, DX and ECT in 0.1 M HCl. The resulting chromogen showed a maximum wavelength of absorption at 502 and 503 nm for DX and ECT, respectively. This method was validated for analytical parameters such as linearity, precision, accuracy, robustness, and ruggedness according to the guidelines of International Conference on Harmonization (ICH) and United States Pharmacopoeia (USP).
Results: The absorbance of the each chromogen formed with DX and ECT was linear over the range of 4 - 30 and 2.5 - 27.5 μg mL-1 for DX and ECT, with 0.9968 and 0.9979 as the regression coefficient, respectively. The limits of detection (LOD) were 0.0045 and 0.0015 μg mL-1 for DX and ECT, respectively, with the limits of quantification (LOQ) at 0.5 and 0.08 μg mL-1. The recovery (accuracy) of the methods resulted in low RSD values of 0.856 – 0.983 % for DX and 0.765 – 0.987 % for ECT.
Conclusion: The developed method shows a high degree of accuracy and precision for the determination of DX and ECT. Thus, tropaeolin 000-1 reagent is versatile for determining the contents of DX and ECT in their formulations.
Keywords: Duloxetine, Escitalopram, Tropaeolin 000-1, Extractive spectrophotometry, Validation
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
